



**SIOP 2003 Copenhagen, Denmark
Annual General Assembly of SIOP Europe – Tuesday, September 23, 2003
from 13.00 to 14.00 hrs.
Room HB4-1, Bella Center**

MINUTES

1. Opening
Prof. M. Stevens opens the meeting and welcomes all SIOP members present.
He apologises for the lack of light and trusts that this problem will be resolved soon.
2. Minutes of the SIOP Annual General Assembly, September 20, 2002 held at SIOP 2002 in Porto, Portugal
No comments are made by the members present and the minutes are approved as a correct record.
3. Report from the President (M. Stevens)
MS notes that he will make this only a short report in which he lists the main priorities of SIOP Europe.
ECCO13: MS notes that at this ECCO meeting the paediatric part is well represented. MS thanks GP and JdK in this respect for their contributions to the paediatric part of the scientific programme.
Nurses Group: At this meeting, the paediatric nurses have a full programme as well. MS notes that the Board of SIOP Europe have been in contact with the Nurses Group and it has been decided to have a closer co-operation with the nurses in order for them to become broader represented in Europe.
Education and Training Committee: MS thanks Prof. Mann for all her efforts to this committee. In co-operation with ESPHI they made many new developments possible in education and training.
Clinical Trials: One of SIOP Europe's main priorities is the support and stimulation of collaborative trials. At present The Board is determining the strategy regarding trials. A database of all European National Groups and Societies is to be set up and a survey amongst these groups and societies is to be organised so there will be a better understanding of the needs of the different countries.
Policies of Europe: The starting point of SIOP Europe is that every child in Europe should have the possibility to be in a clinical trial. SIOP Europe thus wishes to get more children into studies. In order to achieve this, co-operation with ICCCPO has been set up, having so far resulted in the document approved by the Board and Continental Presidents of SIOP Int. at the SIOP 2002 meeting in Porto, Portugal, "Childhood Cancer, Guidelines for Standards of Treatment & Care". Through lobbying through FECS and promotion of collaboration of the societies in cancer care, awareness on a

political level on paediatric oncology should be made.

MS thanks Jill Mann and Jan de Kraker who are stepping down, for all their help and contributions on the Board.

MS also thanks his colleagues of the Board and the SIOP Europe secretariat for all their support during his term as President and welcomes GH as the new President of SIOP Europe.

Dr. J. Pritchard inquires on the role of SIOP Europe in FECS and their part in the ECCO programme.

MS explains that SIOP Europe is a full member society of FECS and that ECCO is the congress of FECS in which all full members are to collaborate to make a congress with multi-disciplinary sessions. None of the societies have their own separate programme. ECCO aims to be a multi-disciplinary meeting presenting the latest developments in oncology. As the interface between paediatric and adult oncology becomes more important, this meeting provides very useful information for both types of oncology.

4. Report from the Treasurer (G. Perilongo)

Dr. Perilongo reports on the finances of SIOP Europe from April 2003 till September 2003. This overview was approved by the SIOP Europe Board.

Status as per April 2003: Euro 149.780,04

Income:

Interests/Varia Euro 2.109,37

Expenses:

Board meetings Euro 883,72

Education & Training Comm meet. Euro 1.547,76

Varia Euro 227,35

ECCO12 Group registration Euro 8.800,00

Secretarial costs Euro 7.724,87

Bank charges Euro 242,50

As per September 15 the money of SIOP Europe available is: Euro 112.463,21

After September 15, the amount of outstanding fees is Euro 19.749,57. These are not calculated in the abovementioned overview. The amount of money invested in market funds is Euro 20.000. This is not in the overview either. If taking these amounts into account, the actual available balance is thus Euro 112.713,64.

Expenses have been made on the Board and Education and Training Committee meetings; meetings of the nurses group; a fellowship for the Flims workshop (This was in the end not used, but will be offered for the same workshop in 2004); scholarships for ECCO12; organisation of the Germ Cell Tumours symposium.

As there is only income from ECCO once every year, SIOP Europe has to be careful in spending their money.

Dr. Cor van den Bos inquires what the amount was that SIOP received from ECCO11. GH notes that this was Euro 76.972,--

The members are asked to formally approve the accounts. The members have no objections and the accounts are approved.

5. Report from the Secretary-General (K. Schmiegelow)

KS notes that the members of SIOP Europe were sent various drafts of the revised statutes of SIOP Europe and have been able to comment on these. Most comments have been incorporated and the latest draft had been sent to the membership in July 2003 for their information. No comments were received on this draft. Therefore KS asks the members to formally approve the revised statutes. No objections are raised from the membership and the revised statutes are approved.

6. Education and Training; Training Courses; Accreditation (J. Mann)

JM summarises the work of the Education and Training Committee. The Education and Training Committee was established in May 2000. It was partly aimed at making paediatric haematology and paediatric oncology a recognised specialty in Europe. Together with ESPHI (European Society of Paediatric Haematology and Immunology), a training programme was made which was approved by CESP (Confederation of European Societies of Paediatrics) in May 2001. Subsequently, the Management Council of the European Union of Medical Specialists (UEMS) established Paediatric Haematology and Oncology as a new Sub-Section within the UEMS Section Paediatrics.

The task then was for each country to implement the programme, within when feasible its existing training structures, and to consider how it will be monitored and how trainees will be evaluated. Guidance in this is provided by CESP, the EBP and the Education and Training Committee of SIOP Europe and ESPHI. This is the present work of the committee.

Under the Erasmus programme the Committee have put forward a grant application to the European Committee.

The new chair of the Committee will be Prof. W. Kamps from The Netherlands.

7. SIOP Europe Clinical Trials (G. Henze)

GH first thanks MS for his efforts as President of SIOP Europe.

GH reports to the members that clinical trials has been an issue for a long time. In the early days of SIOP, one of the aims was that it would be a society that runs clinical trials. However, this was not feasible due to the requirements and costs of such an activity. Due to legal questions, this became even more difficult and therefore SIOP has changed its focus and would now like to play a co-ordinating role in the field of trials. Many trials already exist for quite some time and work fine. This should remain as it is now.

As Prof. Stevens already pointed out, SIOP Europe will establish a Clinical trial committee. This committee will set up a survey among the European national trial groups/societies and will try to establish a database of these groups and the European trials. After this has been set up, SIOP Europe would like to establish some sort of

standardisation of the European trials and perhaps set up rules on how protocols should be written. Through FECS SIOP Europe therefore hopes to be able to do some lobbying in the European Committee.

In Cairo, SIOP Europe will have a discussion on clinical trials with the Board and Continental Presidents of SIOP Int. More information will be provided in due time.

Dr. Kathy Pritchard-Jones inquires how SIOP Europe is going to keep in contact with the trial organisers. GH notes that this would be done via the national societies. This all still has to be discussed.

8. ECCO 13, Paris, France, 2005

GH notes that for ECCO13, the Scientific Committee will be composed of representatives of the 20 specialty subgroups. Paediatric oncology is one of them. The scientific programme of ECCO13 will be developed on the basis of proposals received from these 20 specialty subgroups.

9. Any other important business

Prof. Stevens asks the members if they still have any other issues to discuss.

Dr. Martin Schrappe inquires why the ECCO meeting and the SIOP Meeting are taking place so closely together.

Prof. Stevens notes that this is a problem which has been addressed many times. The proximity cannot be changed, but in order to avoid clashes and conflicts, there will be no SIOP meeting in Europe in the year that ECCO takes place. Another solution could be that SIOP will have a meeting every other year, however, this has not yet been approved.

Dr. C. van den Bos notes that in Lisbon at ECCO12 there were very good mixed sessions. He hopes that for ECCO13, this will be the same as well. Prof. Stevens will take his comments into account.

As there are no other comments, Prof. Stevens thanks the members for their attention and closes the meeting.

MEMBERS PRESENT AT THE AGM

G. Calaminus
N. Carlsen
U. Göbel
J.L. Habrand
M. Hellebostad
C. Karadeniz
H. Kosmidis
G. Masera
G. Miculschi
A. Navajas
A. Oguz
J. Plaschkes
A. Pourtsidis

J. Pritchard
K. Pritchard-Jones
J. Roganovic
M. Schrappe
M. Serban
C. van den Bos
E. Widing
N. Yaris
K. Schmiegelow
G. Henze
M. Stevens
J. de Kraker
J. Mann

G. Perilongo